Drug intelligence / Profile preview

Optive Plus

Development stage
Unknown
Lead developer
Allergan
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Optive Plus is a multi-action artificial tear formulation developed by Allergan (now AbbVie) for the treatment of dry eye disease (DED). It is a lipid-containing emulsion that combines the lubricating properties of carboxymethylcellulose (CMC) and glycerin with the osmoprotective effects of L-carnitine and erythritol. A key feature of the formulation is the inclusion of highly pure castor oil, delivered via a polysorbate-80 micellar system, which replenishes the tear film's lipid layer to reduce tear evaporation. The product is specifically designed to address hyperosmolarity and lipid deficiency, making it particularly effective for patients with evaporative dry eye or mixed-deficiency dry eye. It is typically preserved with PURITE, which breaks down into natural tear components upon contact with the eye.

Brand names
Optive PlusRefresh Optive Advanced
Other names
CGCcarboxymethylcellulose-glycerine-castor oil
02

Targets

GLUT1 (Glucose transporter 1)

Beyond the preview

Go deeper on Optive Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optive Plus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call